Analyst firms · Citizens JMP · NTLA
Citizens JMP NTLA price target and rating history
Intellia Therapeutics Inc. (NTLA) · Health Care
Citizens JMP rates Intellia Therapeutics Inc. (NTLA) Mkt Outperform with a $33 price target, as of its latest action on Oct 6, 2025. It has published 5 rating actions on NTLA since June 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Mkt Outperform
- Price target
- $33
- Median target, all firms
- Too few
- Actions on NTLA
- 5
Citizens JMP price target on NTLA
Every Citizens JMP rating on NTLA
- Oct 6, 2025
- Jan 19, 2023
- Jan 7, 2022
- Aug 6, 2021
- Jun 23, 2021
How other firms rate NTLA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Underweight | $8 | Oct 6, 2026 |
| Wolfe Research | Underperform | $9 | Jul 16, 2026 |
| William Blair | Outperform | Mar 2, 2026 |
Questions about Citizens JMP and NTLA
- What is Citizens JMP's price target for NTLA?
- Citizens JMP's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $33, from its action on Oct 6, 2025.
- What is Citizens JMP's rating on NTLA?
- Citizens JMP rates NTLA Mkt Outperform, a bullish rating, as of Oct 6, 2025.
- When did Citizens JMP last change its view on NTLA?
- On Oct 6, 2025, Citizens JMP upgrades to Mkt Outperform from Mkt Perform, price target $33.
More NTLA rating histories
All Citizens JMP ratingsNTLA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.